Literature DB >> 2859531

Effects of beta-adrenoceptor antagonist administration on beta 2-adrenoceptor density in human lymphocytes. The role of the "intrinsic sympathomimetic activity".

O E Brodde, A Daul, N Stuka, N O'Hara, U Borchard.   

Abstract

Abrupt withdrawal of beta-adrenoceptor antagonists may lead to "rebound-effects". To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years. Propranolol treatment (4 X 40 mg/day) increased the density of beta 2-adrenoceptors by 25% after 2 days; concomitantly PRA and heart rate were reduced. During treatment beta 2-adrenoceptor density remained elevated. After withdrawal of propranolol PRA reached pre-drug levels rapidly, while heart rate was significantly enhanced. Beta 2-Adrenoceptor density, however, declined slowly being still significantly increased after 3 days, although propranolol was not detectable in plasma after 24 h. The affinity of ICYP to beta 2-adrenoceptors was not changed during or after treatment. Mepindolol treatment (2 X 5 mg/day) caused a 30% decrease of beta 2-adrenoceptor density and PRA after 2 days; both parameters remained reduced during treatment. After withdrawal, PRA reached rapidly pre-drug levels, whereas beta 2-adrenoceptor density was still after 4 days significantly diminished. The KD-values for ICYP, however, were not changed. During and after treatment heart rate was not affected. Alprenolol treatment (4 X 100 mg/day) led to a rapid fall in PRA, but did not significantly affect beta 2-adrenoceptor density. It is concluded, that the ISA may play an important role in modulating beta 2-adrenoceptor density and hence tissue responsiveness to beta-adrenoceptor stimulation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859531     DOI: 10.1007/bf00692910

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  15 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  No evidence for temperature-dependent changes in the pharmacological specificity of beta 1- and beta 2-adrenoceptors in rabbit lung membranes.

Authors:  O E Brodde; F Kuhlhoff; J Arroyo; A Prywarra
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-02       Impact factor: 3.000

Review 3.  Effects of drugs on beta-adrenergic receptors on human lymphocytes.

Authors:  P B Molinoff; R D Aarons
Journal:  J Cardiovasc Pharmacol       Date:  1983       Impact factor: 3.105

Review 4.  The beta-adrenergic blockade withdrawal phenomenon.

Authors:  B N Prichard; B Tomlinson; R J Walden; P Bhattacharjee
Journal:  J Cardiovasc Pharmacol       Date:  1983       Impact factor: 3.105

5.  The beta-adrenergic receptor in human lymphocytes: subclassification by the use of a new radio-ligand, (+/-)-125 Iodocyanopindolol.

Authors:  O E Brodde; G Engel; D Hoyer; K D Bock; F Weber
Journal:  Life Sci       Date:  1981-11-23       Impact factor: 5.037

6.  Comparison of changes in the characteristics of beta-adrenoceptors and responsiveness of human circulating lymphocytes during and after chronic administration of pindolol and propranolol.

Authors:  Y Giudicelli; D Lacasa; B Agli; A Leneveu
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 7.  Radioligand binding studies of adrenergic receptors: new insights into molecular and physiological regulation.

Authors:  B B Hoffman; R J Lefkowitz
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

8.  Physiological regulation of beta-receptors in man.

Authors:  A J Wood; R Feldman; J Nadeau
Journal:  Clin Exp Hypertens A       Date:  1982

9.  Changes in the density of beta adrenergic receptors in rat lymphocytes, heart and lung after chronic treatment with propranolol.

Authors:  R D Aarons; P B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

10.  Coexistence of beta 1- and beta 2-adrenoceptors in human right atrium. Direct identification by (+/-)-[125I]iodocyanopindolol binding.

Authors:  O E Brodde; K Karad; H R Zerkowski; N Rohm; J C Reidemeister
Journal:  Circ Res       Date:  1983-12       Impact factor: 17.367

View more
  11 in total

1.  Effects of hydrocortisone on acute β-adrenoceptor blocker and histamine induced bronchoconstriction.

Authors:  Philip M Short; Peter A Williamson; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

2.  Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

3.  The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Selective regulation of beta 1- and beta 2-adrenoceptors in the human heart by chronic beta-adrenoceptor antagonist treatment.

Authors:  M C Michel; A Pingsmann; J J Beckeringh; H R Zerkowski; N Doetsch; O E Brodde
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

Review 5.  Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure.

Authors:  Otto-Erich Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-11       Impact factor: 3.000

6.  Haemodynamic, metabolic, and lymphocyte beta 2-adrenoceptor changes following chronic beta-adrenoceptor antagonism.

Authors:  K Whyte; C R Jones; C A Howie; N Deighton; D J Sumner; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  [How many beta-receptor blockers does the physician need?].

Authors:  D Palm
Journal:  Klin Wochenschr       Date:  1987-03-16

8.  The role of endogenous noradrenaline in the beta-blocker withdrawal phenomenon--studies with cultured heart cells.

Authors:  C Reithmann; A Thomschke; K Werdan
Journal:  Klin Wochenschr       Date:  1987-04-01

9.  Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma.

Authors:  Zsuzsanna Callaerts-Vegh; Kenda L J Evans; Noornabi Dudekula; Donald Cuba; Brian J Knoll; Patrick F K Callaerts; Heather Giles; Felix R Shardonofsky; Richard A Bond
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-06       Impact factor: 11.205

10.  Beta-adrenoceptor antagonists (non-selective as well as beta 1-selective) with partial agonistic activity decrease beta 2-adrenoceptor density in human lymphocytes. Evidence for a beta 2-agonistic component of the partial agonistic activity.

Authors:  O E Brodde; R Schemuth; M Brinkmann; X L Wang; A Daul; U Borchard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.